Sandhoff Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Sandhoff disease, an inherited
lysosomal storage disorder, stems from detrimental genetic mutations within the
HEXB gene. This gene encodes instructions for an enzyme called
β-hexosaminidase, pivotal in breaking down the fatty protein GM2 ganglioside,
which is normally harmless after breakdown within cells. Nonetheless, in
individuals with Sandhoff disease, this degradation process is impaired,
leading to the accumulation of GM2 ganglioside and other molecules within the
brain, causing damage to nerve cells. The disease is categorized into three
types based on the onset of symptoms:
1. Infantile
(Classic) Form - The most severe form of Sandhoff disease, the classic
infantile type, becomes evident shortly after birth. Affected infants between
three to six months of age lose developmental milestones and experience
weakening muscles, hindering activities like rolling over, sitting up, and
crawling. An exaggerated startle response to stimuli emerges. Seizures, vision
and hearing loss, intellectual disabilities, paralysis, enlarged organs, bone
abnormalities, and the distinctive "cherry-red spot" in the eye
characterize the progression of the disease.
2. Juvenile-Onset
Form - A rarer variant occurs when mutations only partially compromise the
enzyme. Signs and symptoms vary, and onset may be in childhood or adolescence.
Muscle weakness, coordination difficulties, speech problems, recurrent
respiratory infections, and seizures are some manifestations of these cases.
3. Late-Onset
Form - Diagnosing the late-onset form can be challenging. Initial indicators
include clumsiness and leg muscle weakness. Over time, affected individuals may
necessitate mobility aid and struggle with speech and swallowing. Mental health
issues, like bipolar disorder or psychotic episodes, affect about 40% of
afflicted adults.
Sandhoff
disease mirrors Tay-Sachs's clinical presentation, featuring startle reactions,
early blindness, progressive motor and mental decline, enlarged head,
cherry-red spots on the macula, doll-like facial appearance, and organ
enlargement. Urinary oligosaccharide levels are elevated. Initial normal
development in children is followed by rapid disease evolution. However, signs
might resemble spinocerebellar ataxia or dystonia in cases with later onset or
in adults, with variable impact on intellectual capacities. Treatment entails
supportive care for symptoms, including seizure management, nutritional
support, and breathing assistance. Unfortunately, a cure is lacking. Severe
infantile-onset cases witness recurrent seizures by age two, leading to muscle and
mental function loss, eventually becoming unresponsive and succumbing to
respiratory infections by age three. Juvenile-onset cases experience similar
issues at a later age but decline progressively. Late-onset cases, while
challenging, do not necessarily curtail lifespan.
Thelansis’s “Sandhoff Disease Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Sandhoff Disease treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Sandhoff Disease across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Sandhoff Disease Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment